AlphAIAlphAI — Financial news for AI agents
theglobeandmail.comOCT 101 min read$BMRN

Bank of America Securities Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)

Bank of America Securities analyst Jason Gerberry maintained a Buy rating on BioMarin Pharmaceutical (BMRN) with a $86.00 price target. BMO Capital also gave a Buy rating, while RBC Capital maintained a Hold. BioMarin reported Q2 revenue of $989.71M and net profit of $44.76M, down from last year's $825.41M revenue and $240.53M profit. Insider sentiment is negative, with recent sales by executives.

Original reporting
theglobeandmail.com
Published Oct 10, 2026, 1:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 10, 2026, 10:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Bank of America Securities Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN) — source image
Source · theglobeandmail.com
Decision brief

The 30-second read

$BMRNBullishMed
01

Why it matters

Positive analyst rating may outweigh insider sell pressure in the short term.

02

Market read

New rating and target provide a fresh catalyst for traders; insider sales add a counterpoint.

03

What to watch

Potential upcoming clinical trial results or regulatory decisions not covered in this note.

Relevance 6/10Novelty 6/10Timing: today

Background

Analyst coverage update and insider activity for BioMarin Pharmaceutical.

Company-level read

Ticker impact

$BMRNBullishMedium confidence
Context

Bank of America Securities analyst maintained a Buy rating on BioMarin and set a new $86 price target.

Expected impact

likely upside as market prices in the $86 target.

Evidence & confidence

Analyst upgrade with a concrete price target is fresh news; the rating is a direct catalyst for short‑term buying.

Market effects

Sector

The buy rating may lift sentiment across small‑cap biotech peers.

Regional

Limited to U.S. biotech investors.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Recent insider selling could signal downside risk despite the rating.

Key entities

  • company
    BioMarin Pharmaceutical

    Biotech firm (NASDAQ: BMRN) receiving a Buy rating and $86 price target.

  • analyst_firm
    Bank of America Securities

    Provided the rating and target.

Read at source← All news

Related articles

OCT 16
$BMRNMed

BioMarin Stock Surges As Wall Street Redraws The Map

BioMarin Pharmaceutical (BMRN) shares rose following a Buy rating from UBS, which cited undervaluation relative to 2027 earnings. The FDA submission for Voxzogo's label expansion and positive clinical data also boosted investor confidence. The company's revenue growth and higher guidance indicate traction in rare-disease drugs, but margin pressure and acquisition financing costs remain concerns.

tipranks.com2 min
OCT 9
$BMRNMedAI 8/10

BioMarin to present data on achondroplasia treatment at ASBMR

BioMarin Pharmaceutical Inc. (BMRN) will present data from 13 studies at the ASBMR 2026 Annual Meeting, including new imaging results for VOXZOGO in treating achondroplasia. The company submitted a supplemental NDA for VOXZOGO to treat hypochondroplasia and expects a 2027 launch if approved. BioMarin also announced data on BMN 333 and BMN 401. VOXZOGO is currently approved in the U.S., Japan, and Australia for achondroplasia.

investing.com1 min
OCT 9
$BMRNMed

BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting

BioMarin Pharmaceutical Inc. (BMRN) presented new data at the American Society for Bone and Mineral Research 2026 Annual Meeting, including results from studies of VOXZOGO® (vosoritide) in children with achondroplasia and hypochondroplasia. The data showed encouraging imaging results from a trial evaluating VOXZOGO's effect on the growth of the foramen magnum and craniocervical junction in children with achondroplasia.

prnewswire.com2 min
OCT 6
$BMRNMed

BIOMARIN PHARMACEUTICAL INC (BMRN): Results of Operations and Financial Condition

BIOMARIN PHARMACEUTICAL INC (BMRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Item 2.02 Results of Operations and Financial Condition Estimated Financial Impact of the Alesta Acquisition In connection with its acquisition of Alesta Therapeutics B.V. (Alesta), a Dutch private limited liability company (besloten vennootschap met beperkte aansprakelijkheid),

SEC EDGAR 8-K2 min